When is targeted therapy recommended for chronic myeloid leukaemia?

CML is driven by a specific genetic change that produces an abnormal signal in leukaemia cells. Targeted medicines block that signal. A blood test and sometimes a bone-marrow test can confirm the change and establish a baseline before treatment.

Treatment is often continued over time, with regular blood tests measuring how the leukaemia responds. Doctors may adjust the medicine for side effects, interactions, an inadequate response or a change in disease phase. The choice also considers pregnancy plans, heart or kidney problems and other health conditions.

Take the medicine exactly as prescribed and ask what to do if you miss or vomit a dose. Keep every monitoring appointment, even when you feel well, because blood results can show response before symptoms change. Give your team an up-to-date list of prescriptions, vitamins and herbal products.

Discuss fatigue, muscle cramps, swelling, skin changes, digestive symptoms and any new health problem. Do not stop treatment without speaking with your haematology team, because interrupted therapy can affect disease control.

Report promptly any fever, unusual bleeding, severe weakness, new swelling, chest discomfort, breathlessness or a sudden change in vision. Seek urgent care for severe chest pain, serious breathing difficulty, fainting, uncontrolled bleeding or sudden neurological symptoms.

Ask: Which test confirms the CML target? What result will show that treatment is working? How often will blood tests be done? Which medicines or foods interact with this treatment? What should I do if side effects make it hard to take every dose?